INmune Bio (NASDAQ:INMB) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of INmune Bio (NASDAQ:INMB) from a sell rating to a hold rating in a research report report published on Saturday.

Separately, Weiss Ratings lowered shares of INmune Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy”.

INmune Bio Trading Up 1.4%

Shares of INmune Bio stock opened at $2.12 on Friday. The company’s 50-day moving average price is $1.64 and its two-hundred day moving average price is $1.48. INmune Bio has a 52 week low of $1.09 and a 52 week high of $2.61. The stock has a market cap of $56.35 million, a PE ratio of -3.16 and a beta of 0.97.

INmune Bio (NASDAQ:INMB) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.16.

Institutional Investors Weigh In On INmune Bio

Several hedge funds have recently modified their holdings of INMB. Jain Global LLC acquired a new stake in INmune Bio during the 4th quarter worth about $66,000. Charles Schwab Investment Management Inc. lifted its stake in INmune Bio by 20.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 50,252 shares of the company’s stock valued at $78,000 after buying an additional 8,427 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in shares of INmune Bio by 79.0% in the fourth quarter. Wells Fargo & Company MN now owns 24,857 shares of the company’s stock worth $39,000 after buying an additional 10,970 shares during the period. Bank of Montreal Can acquired a new position in shares of INmune Bio in the fourth quarter worth about $41,000. Finally, Goldman Sachs Group Inc. increased its position in shares of INmune Bio by 269.0% in the fourth quarter. Goldman Sachs Group Inc. now owns 56,477 shares of the company’s stock worth $88,000 after acquiring an additional 41,173 shares in the last quarter. 12.72% of the stock is owned by hedge funds and other institutional investors.

INmune Bio Company Profile

INmune Bio, Inc is a clinical-stage immunology company based in San Diego, California, focused on harnessing the innate immune system to combat a range of serious diseases. The company’s research and development efforts concentrate on modulating cellular pathways to restore and enhance the body’s natural defenses, particularly in oncology and neurodegenerative conditions.

The company’s lead therapeutic candidate, XPro1595 (also referred to as INB03), is a proprietary selective inhibitor of soluble tumor necrosis factor (TNF) designed to reduce chronic inflammation without impairing membrane-bound TNF functions.